On October 01, 2015 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, reported that interim results of an ongoing Phase 1 dose escalation study of MGA271 will be presented by the Company in the late-breaking abstract session at the 2015 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in National Harbor, MD (Press release, MacroGenics, OCT 1, 2015, View Source [SID:1234507629]). The 30th Anniversary Annual Meeting is being held November 4-8, 2015 at the Gaylord National Hotel & Convention Center. Presentation details include:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Interim Results of an Ongoing Phase 1, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3
Session: Late-Breaking Abstract Session
Time: Saturday, November 7, 2015, from 12:00 pm – 12:15 pm ET
Presented by: MacroGenics, Inc.
Background on MGA271
MGA271 is a humanized, Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules that are involved in immune regulation. B7-H3 is over-expressed by a wide variety of solid tumor cells as well as cancer stem-like cells and the supporting tumor vasculature. MGA271 is currently undergoing Phase 1 testing both as monotherapy and in combination with checkpoint inhibitors including ipilimumab and pembrolizumab across a wide range of solid tumors.